

Daily evidence digest

12 November 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Comirnaty (Pfizer) vaccine for children, Spikevax (Moderna) in cancer patients receiving treatment, aerosol generating procedures

Peer reviewed journals featured:

- A randomised controlled trial of Comirnaty (Pfizer) vaccine in children 5 to 11 years of age [here](#)
- A prospective multicentre noninferiority trial of Spikevax (Moderna) vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours [here](#)
- Observational studies on:
 - Association between low-income neighbourhoods and severe COVID-19 in Paris [here](#)
 - Changes in behavioural determinants of health during COVID-19 [here](#)
 - Comparative sensitivity of 122 rapid diagnostic tests [here](#)
 - Association between sleep-related hypoxia, risk of COVID-19 hospitalisations and mortality [here](#)
- Commentary on:
 - Non-invasive respiratory support in managing acute COVID-19 pneumonia [here](#)
 - 3D printing and additive manufacturing (3DP/AM) technologies for PPE production during COVID-19 [here](#)
- An editorial on aerosol generating procedures [here](#)

Guidance and reports

- The World Health Organization published COVID-19 social media Q&As [here](#)
- The Therapeutic Goods Administration (TGA) granted provisional determination to Spikevax (Moderna) for proposed use in children, and booster shot for adults [here](#)

News and blogs

- Pandemic reduced life expectancy in most developed countries [here](#)
- Singaporeans who remain “unvaccinated by choice” must fund their own treatment [here](#)
- COVID-19 antiviral pills [here](#)

[Click here](#) to subscribe to the daily evidence digest.